Why the study?
What are the fetal and maternal safety effects of antithrombotic agents during pregnancy?
What are the fetal and maternal safety effects of antithrombotic agents during pregnancy?
This review provides clinical recommendations for the use of antithrombotic agents during pregnancy while highlighting the need for better quality evidence.
Answers are grounded in this paper and cite their sources.
Recommendations for antithrombotic agents in pregnancy warrant caution; leaves open the need for high-quality prospective studies on fetal and maternal safety.
Introduction Antithrombotic therapy during pregnancy is used for the treatment and prophylaxis of venous thromboembolic disease, for the prevention and treatment of arterial embolism associated with valvular heart disease and/or prosthetic heart valves, for the prevention of fetal growth retardation and pregnancy loss in patients with antiphospholipid antibodies, and in patients with pregnancy-induced hypertension. Since antithrombotic agents have the potential to produce complications in both the mother and fetus, their use during pregnancy raises concerns. Guidelines are difficult to establish because the evidence upon which recommendations are based is derived primarily from poor-quality studies. This chapter reviews the fetal and maternal effects of antithrombotic agents including oral anticoagulants, unfractionated heparin, low molecular weight heparins (LMWH), and aspirin, and provides recommendations for their use during pregnancy.
No takes yet. Share an insight, caveat, or question.
JS Ginsberg (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: